Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Phase 3 Aspire failed to achieve the primary endpoint, showing no significant change from baseline in Bayley-4 cognitive raw score. The trial also missed the key secondary endpoint, net response in the Multidomain Responder Index (MDRI), increasing clinical and regulatory uncertainty around the program.